News
Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1
PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners.
Sigma1 Pharmacology in the Context of Cancer
Kim, FJ and Maher, CM. Handbook of Experimental Pharmacology.
Researchers at Sidney Kimmel Cancer Center at Thomas Jefferson University Promise New Directions for Targeting Prostate Cancer
A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.